Pain, policy, and the opioid dilemma in sub-Saharan Africa: a systematic review of access, regulation, and health governance from 1990 to 2024

Sub-Saharan Africa (SSA) faces a dual opioid dilemma: widespread undertreatment of moderate to severe pain due to limited access to essential opioid analgesics, alongside increasing concern about misuse and diversion in selected contexts. Opioids are clinically indicated for severe cancer-related pain, advanced chronic illness, major trauma, surgery, and end-of-life care, yet regional consumption remains disproportionately low relative to documented disease burden, indicating systemic under-provision rather than low need. This systematic review synthesizes evidence on opioid policy, regulation, access, and governance in SSA to examine how legal frameworks, institutional arrangements, political dynamics, and data systems shape medical availability. Following PRISMA and SWiM guidance, we reviewed peer-reviewed and grey literature addressing national drug control laws, regulatory implementation, procurement and supply systems, prescribing authority, and surveillance capacity; 33 studies met inclusion criteria. Across settings, restrictive or ambiguously interpreted legislation, multi-layered administrative controls, fragmented mandates across health and enforcement institutions, weak forecasting and distribution systems, concentrated prescribing authority, professional risk aversion, and chronic data gaps were consistently associated with constrained access. Concurrently, rising political and media attention to non-medical use, particularly of tramadol, has reinforced enforcement-oriented narratives that may further limit reform space. Persistent deficiencies in routine consumption data and unmet need assessment contribute to conservative import quotas and regulatory inertia. Addressing this imbalance requires proportionate, sequenced reform that strengthens data and forecasting systems, clarifies and aligns legal mandates with public health objectives, invests in workforce capacity and supply chains, and embeds safeguards against diversion while correcting avoidable under-treatment.